FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

NL Life Sciences BV

2. Date of Event Requiring Statement (MM/DD/YYYY)
11/13/2018 

3. Issuer Name and Ticker or Trading Symbol

Natur International Corp. [NTRU]

(Last)        (First)        (Middle)

124 JACHTHAVENWEG

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

AMSTERDAM, P7 1081KJ       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   20602133   I   Held through NL Life Sciences BV  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Preferred Stock     (1)   (1) Common Stock   61849000     (1) I   Held through NL Life Sciences BV  

Explanation of Responses:
(1)  The Series B Preferred Stock is convertible automatically upon the issuer increasing its authorized number of shares of common stock. The conversion rate is 1,000 shares of common stock for each outstanding share of Series B Preferred Stock. The person with the voting and dispositive power over the shares is Rhys Tombling, the director of the reporting person, who disclaims any beneficial ownership of the shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
NL Life Sciences BV
124 JACHTHAVENWEG
AMSTERDAM, P7 1081KJ
X


Signatures
/s/ Rhys Tombling 8/13/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Natur (CE) (USOTC:NTRU)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Natur (CE) Charts.
Natur (CE) (USOTC:NTRU)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Natur (CE) Charts.